MedImmune

MedImmune, LLC is an American biotechnology company, which was acquired by AstraZeneca in 2007. The company's primary products are Synagis, FluMist, and Imfinzi, which are used for the prevention of Respiratory Syncytial Virus (RSV) and treatment of influenza and bladder cancer respectively.

History

MedImmune was founded in 1988 by Wayne Hockmeyer. It was initially a privately held company, but became publicly traded in 1991. In 2007, it was acquired by AstraZeneca for $15.6 billion.

Products

MedImmune has three primary products: Synagis, FluMist, and Imfinzi.

Synagis

Synagis is a monoclonal antibody used for the prevention of serious lower respiratory tract disease caused by RSV in pediatric patients.

FluMist

FluMist is a nasal spray influenza vaccine that protects against four strains of influenza.

Imfinzi

Imfinzi is a human monoclonal antibody that is designed to bind with PD-L1 and block the interaction of PD-L1 with PD-1 and CD80.

Research and Development

MedImmune conducts research in several areas of study, including oncology, respiratory, cardiovascular and metabolic disease, and infection and vaccines.

See Also

• AstraZeneca
• Biotechnology
• Monoclonal Antibodies
• Respiratory Syncytial Virus (RSV)
• Influenza
• Bladder Cancer

• MedImmune
  MedImmune